A new publication describing tesamorelin appeared on July 8, 2026. The article, titled "Tesamorelin as an Adjunct to Exercise for Improving Physical Function in HIV (TRIUMPH): a clinical trial protocol," was published in BMJ Open.
This publication presents a clinical trial protocol rather than trial results. It outlines a planned study examining tesamorelin used alongside exercise in people living with HIV, focused on physical function.
As a protocol paper, the publication describes the design of the planned trial. No outcomes, efficacy data, or safety findings are reported in this publication. Readers should not interpret this listing as evidence of benefit or risk associated with tesamorelin.
Tesamorelin remains an approved compound, and this publication adds to the published literature describing ongoing and planned research involving it. Further updates may follow as the TRIUMPH trial progresses and results become available in subsequent publications.
For more background on tesamorelin, readers can consult the compound overview.